Skip to main content

Year: 2024

AMERICAN SALARS ENGAGES EXPLORATION TEAM FOR PHASE 1 PROGRAM ON ITS 100% OWNED LAC SIMARD NORD PROPERTY WITHIN SAYONA MINING’S TANSIM LITHIUM PROJECT, QUEBEC

VANCOUVER, BC, Nov. 26, 2024 (GLOBE NEWSWIRE) — AMERICAN SALARS LITHIUM INC. (“AMERICAN SALARS” OR THE “COMPANY”) (CSE: USLI, OTC: USLIF, FWB: Z3P, WKN: A3E2NY) announces it has engaged an exploration team to conduct a Phase 1 program on its 100% owned 3,958 acre Lac Simard Lithium Project in Quebec, Canada. The Phase 1 exploration and reconnaissance will be specifically focused on the Lac Simard Nord block directly contiguous to Sayona Mining Limited’s (ASX: SYA) (“Sayona”) “Tansim” Project which hosts the Viau-Dallaire and Viau Showings estimated by Sayona as having the potential to contain between 5 to 25 million tons of Li20 @ 1.2-1.3%.Sayona and Piedmont Limited (NASDAQ: “PLL”) (“Piedmont”) recently announced a merger to create a USD $623 million (CAD $870 Million) lithium giant1 after announcing...

Continue reading

Siili Solutions Plc updates its long-term financial targets for 2025-2028

Siili Solutions Plc updates its long-term financial targets for 2025-2028 Siili Solutions Plc Stock exchange release 26 November 2024 at 09:30 EET The Board of Directors of Siili Solutions Plc has approved updated financial targets for years 2025-2028. Financial targets remain the same, but the target period will be longer. Previously the financial targets were set for the years 2025-2026. Financial targets 2025-2028Annual revenue growth of 20 percent, of which organic growth accounts for about half Adjusted EBITA 12 percent of revenue Net debt-to-EBITDA < 2 The aim is to pay a dividend corresponding to 30–70 percent of net profit annually“The overall state of the IT service market has remained challenging, and recovery of the markets is taking longer than expected. We are committed to keeping our financial targets...

Continue reading

ArcelorMittal provides update on its European decarbonization plans

26 November 2024, 08:30 CET ArcelorMittal is today providing an update on its decarbonization plans in Europe. The Company has previously announced the intention to invest in lower carbon emissions “hydrogen ready” DRI-EAF facilities to replace several blast furnaces across our European business, as a key strategic first step towards reducing emissions. In all cases, the host countries offered funding support for these projects, with the approval of the European Commission. These projects were premised on a favourable combination of policy, technology and market developments that would facilitate decarbonization investment by helping offset the significantly higher capital and operating costs that this transition strategy would involve. This included being able to use natural gas until green hydrogen became competitive. However European...

Continue reading

ONWARD Medical Provides Q3 2024 Update and Year-to-Date Highlights

Raised EUR 50 million in new capital with cornerstone investment from Ottobock, now the Company’s top investor Signed exclusive license with CEA to develop and commercialize WIMAGINE Brain-Computer Interface (BCI) as part of the Company’s investigational ARC-BCI System Rob ten Hoedt, former Medtronic President and Executive Committee member, joined Board of Directors as incoming Chairman EINDHOVEN, the Netherlands, Nov. 26, 2024 (GLOBE NEWSWIRE) —  ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today provided a Q3 2024 Business Update. “We secured EUR 50 million in additional capital, added Ottobock as a strategic investor and partner, and gained exclusive rights to...

Continue reading

Sampo plc’s share buybacks 25 November 2024

Sampo plc, stock exchange release, 26 November 2024 at 8:30 am EET Sampo plc’s share buybacks 25 November 2024 On 25 November 2024, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  4,303 39.99 AQEU          38,422 40.00 CEUX  245 40.02 TQEX  51,141 40.01 XHELTOTAL 94,111 40.01  *rounded to two decimals                 On 17 June 2024, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. On 16 September 2024, the Board of Directors...

Continue reading

Nokia and du conclude successful transport network slicing trial in UAE

Press ReleaseNokia and du conclude successful transport network slicing trial in UAENokia network slicing technology will help du tailor segments customized to user needs. The first of its kind in the region, the live transport network slicing deployment will cater to specific requirements for bandwidth, latency, and reliability.26 November 2024Dubai, United Arab Emirates – Nokia today announced that it has successfully completed a network slicing trial with du, the leading telecom and digital services provider. This trial is the UAE’s first live transport slicing deployment which will allow the service provider to operate a variety of network services that cater to different needs while remaining within the existing network infrastructure. Network slicing allows operators to flexibly allocate resources for optimal performance and...

Continue reading

Roche reports update on Phase III SKYSCRAPER-01 study results

Basel, 26 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq® (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC).  SKYSCRAPER-01 is a global phase III, randomised, double-blind study evaluating tiragolumab plus Tecentriq compared to Tecentriq alone in 534 patients with PD-L1-high previously untreated, locally advanced unresectable or metastatic NSCLC. Patients were randomised 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until disease progression, loss of clinical benefit, or unacceptable toxicity. The study did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed...

Continue reading

AB Kauno energija business activity results of the 9 months of the year 2024

The Management Board of AB Kauno Energija (hereinafter – the Company) (code – 235014830) assessed the results of Company’s business activity of 9 months of the year 2024 and financial state as at September 30, 2024 and approved AB Kauno Energija consolidated and Company’s non-audited results of 9 months of the year 2024. The result of Company’s business activities of 9 months of the year 2024 according to the International Financial Reporting Standards as adopted by the European Union is profit in amount of EUR 954 thousand (the result of 9 months of the year 2023 was profit amounted to EUR 534  thousand), turnover from sales is EUR 53,657 thousand (in 9 months of the year 2023 it was amounted to EUR 56,210 thousand). The result of activities of the Group which consists of AB Kauno Energija and its’ subsidiaries UAB GO Energy LT (code...

Continue reading

Havila Kystruten AS: Invitation to Q3 2024 Earnings Call

Havila Kystruten AS will publish its Q3 2024 financial report on Wednesday, November 27, 2024. Bent Martini, CEO, and Aleksander Røynesdal, CFO, will present the results in an earnings call at 10:00 CET on Thursday, November 28, 2024, followed by a Q&A session. The earnings call can be accessed live via webcast. A recording will be available on demand at the Company’s website after the live event has concluded. The earnings call can be accessed through the following link: https://www.appairtime.com/event/822ef1cf-43da-4636-b027-e301921f578b Contacts: Chief Executive Officer: Bent Martini, +47 905 99 650 Chief Financial Officer: Aleksander Røynesdal, +47 413 18 114   This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Continue reading

Vow ASA: Results for the third quarter 2024

Oslo, 26 November 2024: In the third quarter, Vow ASA (“Vow” or the “Company”) (OSE ticker: VOW) had revenues of NOK 267.4 million, representing an increase of 5.0 percent relative to the third quarter in 2023. EBITDA before non-recurring items was NOK 18.4 million, resulting in an EBITDA margin of 6.9 per cent, compared to negative NOK 15.5 million in the third quarter last year. The Vow group has continued to deliver on cost reduction programmes. For the full year 2024, annual cost savings are estimated to be in the range of NOK 40-50 million compared to full year 2023. “This is the third consecutive quarter with a positive EBITDA result and we are working our way back after a challenging period. The positive trend this year is a result of our wide-ranging efforts to improve the gross margin in projects,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.